Germany· DE-A57-9e6a8579ea16d8dd
Cleviprex
A clevidipine product containing clevidipine, registered in Germany by Chiesi Gmbh. The same ATC class is registered in 8 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Clevidipine is registered in 8 of 19 countries.
Countries holding a registration under ATC C08CA16 (clevidipine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 4 of them publish a price we can compare per daily dose
Clevidipine · ATC C08CA16
8 / 19 countries
- Belgiumprice
- Canada
- Franceprice
- Germany
- Netherlands
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Clevidipine
- Manufacturer
- Chiesi Gmbh
- Country
- Germany (DE)
- ATC code
- C08CA16
- ATC class
- Clevidipine
- Defined daily dose
- 0.12 g, P
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
92 interactions on record for clevidipine.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clevidipine · interactions on record
92 records
- 5 severe
- 85 moderate
- 1 minor
Most severe, free to view
- DolasetronA04AA04severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
- SiponimodL04AA42severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Clevidipine in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCleviprexChiesi USA, Inc.
- BelgiumCleviprex 0.5 mg/mlChiesi
- SwitzerlandCleviprex, emulsion pour perfusionChiesi SA
- SpainCLEVIPREX 0,5MG/ML EMULSION INYECTABLEChiesi España S.A.U.
- FranceCLEVIPREX 0,5 mg/ml, émulsion injectableCHIESI
- United KingdomCleviprex 25mg/50ml emulsion for infusion vialsChiesi Ltd
- NetherlandsCleviprex 0,5 mg/ml, emulsie voor injectieChiesi Pharmaceuticals B.V.
- SwedenCleviprex 0,5 mg/ml Injektionsvätska, emulsionChiesi Farmaceutici S.p.A.
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- Austria · Cleviprex
- Belgium · Cleviprex
- Spain · Cleviprex
- France · Cleviprex
- Italy · Cleviprex
- Luxembourg · Cleviprex
- Netherlands · Cleviprex
- Sweden · Cleviprex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/70fbc1e1-8bcd-42f7-8bb8-0158d1d72d81 GET /v1/drugs/70fbc1e1-8bcd-42f7-8bb8-0158d1d72d81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Clevidipine",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about clevidipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.